HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

De novo malignancies after liver transplantation: a single-center experience.

AbstractBACKGROUND AND OBJECTIVES:
The recipients of liver transplantation (LT) are subjected to lifelong immunosuppression with its many drawbacks. De novo and recurrent malignancy in transplant recipients are attributed to attenuation of immunosurveillance. In the present study, we present our experience with de novo malignancies encountered after both deceased and living donor liver transplantations.
DESIGN AND SETTING:
Retrospective study of patients referred to LT center between April 2001 and January 2010.
PATIENTS AND METHODS:
Various data were collected including type of malignancy and histopathologic features, immunosuppression regimen, and patient survival.
RESULTS:
Of 248 LT procedures performed in 238 patients (10 retransplants), 8 patients (3.4%) developed de novo post-LT malignancies. De novo malignancies included post-LT lymphoproliferative disorders (PTLD) in 5 patients who were all Epstein-Barr virus (EBV) positive, and who were treated successfully with anti-CD20 monoclonal antibody therapy, reduction of immunosuppression, and control of EBV activity; urinary bladder cancer in 1 patient who was treated with radical surgical resection and chemotherapy but died of bone and lung metastasis within 1 year of diagnosis; endometrial carcinoma in 1 patient who was treated with radical surgical resection; and Kaposi sarcoma in 1 patient who was successfully treated with surgical excision and reduction of immunosuppression.
CONCLUSION:
EBV-associated PTLD is the most frequently encountered de novo malignancy after LT and is easily treatable by chemotherapy and reduction of immunosuppression.
AuthorsBassem Hegab, Hatem Khalaf, Naglaa Allam, Ayman Azzam, Faisal Aba Al Khail, Waleed Al-hamoudi, Yasser Kamel, Hamad Al Bahili, Mohammed Al Sofayan, Mohammed Al-Sebayel
JournalAnnals of Saudi medicine (Ann Saudi Med) 2012 Jul-Aug Vol. 32 Issue 4 Pg. 355-8 ISSN: 0975-4466 [Electronic] Saudi Arabia
PMID22705604 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Antigens, CD20
  • Immunosuppressive Agents
Topics
  • Adolescent
  • Adult
  • Aged
  • Antibodies, Monoclonal (therapeutic use)
  • Antigens, CD20 (immunology)
  • Child
  • Child, Preschool
  • Epstein-Barr Virus Infections (etiology)
  • Female
  • Humans
  • Immunosuppression Therapy (adverse effects)
  • Immunosuppressive Agents (administration & dosage, adverse effects, therapeutic use)
  • Infant
  • Liver Transplantation (methods)
  • Lymphoproliferative Disorders (etiology)
  • Male
  • Middle Aged
  • Neoplasms (epidemiology, etiology, pathology)
  • Retrospective Studies
  • Survival Rate
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: